Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Lung cancer screening gets a Heart-Smart upgrade for heavy smokers

NCT ID NCT07301489

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether adding a heart disease prevention program to standard lung cancer screening can improve the health of heavy smokers. Researchers will use chest CT scans already taken for lung cancer screening to also check for hidden heart disease. 1000 participants will be followed for one year to see if this combined approach helps them reach goals like lower blood pressure, better cholesterol, and quitting smoking.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Apr 2041

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 to 79 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria used for the lung cancer screening implementation study/ TIDL Study: * Women and men * Ages 60 to 79 years old (inclusive) * A smoking history of at least 35 pack-years and 1) being a current smoker or a former smoker who quit less than 10 years prior or 2) having a PLCOm2012 model 6-year risk for lung cancer incidence over 2.6%. * Willingness and ability to comply with scheduled visits, laboratory tests, and other trial procedures * Written informed consent obtained prior to performing any protocol-related procedures * The participant should be affiliated to a social security system Exclusion Criteria used for the lung cancer screening implementation study/ TIDL Study: * Recent abnormal pulmonary findings under work-up of standard care * Having had chest CT \<1 year before potential entry into the study * Current or prior history of lung cancer, renal cancer, melanoma or breast cancer * Inability to provide signed informed consent * Insufficient understanding of the languages in which trial information is available * Psychiatric or other disorders that are incompatible with compliance to the protocol requirements and follow-up * Unable to be followed-up for at least 5-years * Body weight \>140 Kg because of difficulty of conducting the CT exam Inclusion Criteria used for the ACE 5 Study: * Participants from the TIDL Study with non-contrast, non-cardiac chest CT images available as part of the implementation lung cancer screening study * Signed consent for cardiovascular add on-study and agree to protocol, including follow-up visit 1-year after the baseline examination Exclusion Criteria used for the ACE 5 Study: * Any surgical or medical condition, including short life-expectancy, based on medical records or clinical findings prior to randomization, that will impair the ability of the patient to participate in the study * Patients unwilling or unable to comply with the protocol * History of non-compliance to medical management and patients who are considered potentially unreliable, based on information obtained prior to randomization * History or evidence of alcohol or drug abuse with the last 12 months, based on information obtained prior to randomization, that will influence study participation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular disease prevention are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Akershus University Hospital

    RECRUITING

    Lørenskog, Akershus, 1478, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.